US.ABT · Abbott Laboratories

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.943392618091413,
        "turnoverUsdM": 1611.9377643599998,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.8,
    "stopLevels": {
      "symbol": "US.ABT",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 98.4236,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.7,
      "stop_loss_percent": 5.9,
      "take_profit_price": 115.1895,
      "target_multiplier": 2.2,
      "technical_strength": 2.35,
      "take_profit_percent": 10.1
    },
    "positionPoints": 1.8,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.7157072314989281,
    "stopLossPercent": 5.886785236182826,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 78.1,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 61.1,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 17
  },
  "market": {
    "ma20": 96.3075,
    "ma50": 91.6962,
    "close": 104.58,
    "prevClose": 103.06,
    "avgVolume20": 13058342,
    "volumeRatio": 1.18,
    "changePercent": 1.47
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 17,
    "details": {
      "ret_5d": 0.028723194963604204,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 17,
      "vcp_bonus": 0,
      "vol_ratio": 1.1756181962752437,
      "ret_points": 4,
      "vol_points": 2,
      "range_ratio": 0.9176595800925628,
      "volat_points": 0,
      "day_range_pct": 0.02371390323197556,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 8,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": true,
      "return_window_days": 5,
      "first_breakout_bonus": 2,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 78.1,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 52,
        "contribution": 2.6
      },
      {
        "raw": 14,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 70,
        "contribution": 14
      },
      {
        "raw": 4.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 30.67,
        "contribution": 4.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 22.5,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 75,
        "contribution": 22.5
      },
      {
        "raw": 8,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 80,
        "contribution": 8
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 61.1,
    "details": [
      "基本面分析總分: 2.6/5分",
      "資金流分析總分: 14/20分",
      "市場環境分析總分: 4.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 22.5/30分",
      "情緒分析: 8/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.6,
      "資金流": 14,
      "市場環境": 4.6,
      "情緒分析": 8,
      "技術信號": 22.5,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.4,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 1611.9377643599998,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 3.2,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.ABT",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 710.4899991500001,
                "ma50": 717.6342017599999,
                "name": "QQQ",
                "close": 682.059998,
                "points": 0.4
              },
              "spy": {
                "ma20": 746.6545068500001,
                "ma50": 745.00220184,
                "name": "SPY",
                "close": 739.02002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.943392618091413,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "優秀",
        "items": {
          "sentiment": {
            "score": 8,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 6,
              "sentimentScoreRaw": 1.8
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141037230,
                "url": "https://finnhub.io/api/news?id=a9aa1fd74151e85171ee00dcd3cf842503898c22892f78b0e8379b31a30a66b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Let’s dive deeper […]",
                "category": "company",
                "datetime": 1785184916,
                "headline": "Abbott (ABT) Raised Its Profit Forecast. What’s Driving Its Growth?"
              },
              {
                "id": 141032969,
                "url": "https://finnhub.io/api/news?id=926ce0a2ebf19b1581d142bdeb833c62f58d3b64234bb49efe03cea689cda9df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the “Jensen Quality Growth Equity Strategy”. A copy of the letter is available to download here. The fund seeks long-term growth by investing in high-quality companies with durable competitive advantages. It returned 10.94% net of fees in […]",
                "category": "company",
                "datetime": 1785156078,
                "headline": "Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth"
              },
              {
                "id": 140997749,
                "url": "https://finnhub.io/api/news?id=d53c2fad77b0b9e5d6dad30ac140cc93918ffb8a8e510220c597fd23ab667409",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "ISRG's expanding robotic surgery ecosystem and innovation pipeline give it an edge over Abbott for investors seeking stronger long-term MedTech growth.",
                "category": "company",
                "datetime": 1784830140,
                "headline": "ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now?"
              },
              {
                "id": 140990040,
                "url": "https://finnhub.io/api/news?id=7fccb43adc3462ddbaea3052709efe889674ebf1ceae5bca76dd5849170a945b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories earnings put recent stock moves in context Abbott Laboratories (ABT) is back in focus after its latest quarterly earnings, where higher year over year sales came alongside lower net income and earnings per share, sharpening attention on upcoming estimates. See our latest analysis for Abbott Laboratories. After these earnings, Abbott Laboratories' recent rally stands out, with a 7 day share price return of 12.66% and a 30 day share price return of 14.51% contrasting with a...",
                "category": "company",
                "datetime": 1784769014,
                "headline": "Abbott Laboratories (ABT) Earnings Drew Fresh Attention, Is It Still Below Fair Value?"
              },
              {
                "id": 140971694,
                "url": "https://finnhub.io/api/news?id=6e2b21a1f482923310edb5a75efae7de93dc3eae30084384a0913f2a0c2bbc46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1784638802,
                "headline": "Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140933088,
                "url": "https://finnhub.io/api/news?id=83ec2d6328e7b92edab50ec62e7a6e350ba5c5a3931b3f10a35569daf00a30f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care.",
                "category": "company",
                "datetime": 1784296800,
                "headline": "ABT Q2 Earnings Call Flags Stronger Second-Half Setup"
              },
              {
                "id": 140926174,
                "url": "https://finnhub.io/api/news?id=534c87dc30bc88037da24a5ce93963067da47b66a5ba7b868f84d197c9441c0e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories (ABT) reports robust sales growth and raises full-year EPS guidance, driven by strong performance in Nutrition, Medical Devices, and Emerging Markets.",
                "category": "company",
                "datetime": 1784235623,
                "headline": "Abbott Laboratories (ABT) Q2 2026 Earnings Call Highlights: Strong Growth in Key Segments and ..."
              },
              {
                "id": 140926177,
                "url": "https://finnhub.io/api/news?id=027d3633509cd297ac4a3e4973aac87bc8d81786e557a57dd25ed60dca1110fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories has reported its second-quarter 2026 results, with sales rising to US$12.59 billion from US$11.14 billion a year earlier, while net income fell to US$928 million and diluted EPS from continuing operations declined to US$0.53. Despite lower net income, Abbott delivered better-than-expected adjusted earnings, lifted its full-year 2026 adjusted EPS guidance, and highlighted strong growth in higher-margin Medical Devices and Cancer Diagnostics, signalling a continued shift in...",
                "category": "company",
                "datetime": 1784232877,
                "headline": "Abbott (ABT) Lifts 2026 EPS Outlook Amid Business Mix Shift Toward Devices and Diagnostics"
              }
            ],
            "raw_source": [
              {
                "id": 141037230,
                "url": "https://finnhub.io/api/news?id=a9aa1fd74151e85171ee00dcd3cf842503898c22892f78b0e8379b31a30a66b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Let’s dive deeper […]",
                "category": "company",
                "datetime": 1785184916,
                "headline": "Abbott (ABT) Raised Its Profit Forecast. What’s Driving Its Growth?"
              },
              {
                "id": 141035101,
                "url": "https://finnhub.io/api/news?id=1030c034e8cbe3e61dd6ad76c34fbb29b759a77e80edf8b047749530be1c2491",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "The chief investment strategist at Concurrent Asset Management shares her top investment picks right now.",
                "category": "company",
                "datetime": 1785167040,
                "headline": "Leah Bennett: Where to Invest After the AI-Chip Stock Surge"
              },
              {
                "id": 141037231,
                "url": "https://finnhub.io/api/news?id=5ac53997dd77707f7014e447d61f5d8a9c72654ff2e28d4e6ef21dce40cd3a6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott will market Freenome’s SimpleScreen CRC test in the U.S., alongside its Cologuard stool test. SimpleScreen will compete with Guardant Health’s Shield blood test for colorectal cancer screening.",
                "category": "company",
                "datetime": 1785166670,
                "headline": "Freenome secures FDA nod for blood-based colorectal cancer test"
              },
              {
                "id": 141032969,
                "url": "https://finnhub.io/api/news?id=926ce0a2ebf19b1581d142bdeb833c62f58d3b64234bb49efe03cea689cda9df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the “Jensen Quality Growth Equity Strategy”. A copy of the letter is available to download here. The fund seeks long-term growth by investing in high-quality companies with durable competitive advantages. It returned 10.94% net of fees in […]",
                "category": "company",
                "datetime": 1785156078,
                "headline": "Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth"
              },
              {
                "id": 141033911,
                "url": "https://finnhub.io/api/news?id=3609c866b6c1c8cb9e463baa69526262f4a9897a86ea509014ba2e333ed00030",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "ABT's earnings beat and higher profit outlook strengthen its case, but can growth in devices and diagnostics overcome valuation and acquisition concerns?",
                "category": "company",
                "datetime": 1785156060,
                "headline": "Is Abbott Stock Attractive After Its Earnings and Guidance Update?"
              },
              {
                "id": 141032970,
                "url": "https://finnhub.io/api/news?id=160e98bc231a23828bb9db0e3b6c5342e49426cb05277ae747daa0a052a35aa5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Freenome is a biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone. – Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based colorectal cancer screening – BRISBANE, Calif. and ABBOTT PARK, Ill., July 27, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer d",
                "category": "company",
                "datetime": 1785153600,
                "headline": "FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S."
              },
              {
                "id": 141032152,
                "url": "https://finnhub.io/api/news?id=c9cdc9b27f60fb3ee8e170927c5226a3a2b0d43646e685a4c0755d0565d70fa0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "GM, ABT and JNJ stand out this earnings season after raising guidance, boosting outlooks and reinforcing momentum with stronger-than-expected quarterly results.",
                "category": "company",
                "datetime": 1785145260,
                "headline": "Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson"
              },
              {
                "id": 141033409,
                "url": "https://finnhub.io/api/news?id=059129dcf1145174f5408b355d797d083baf7838fa85a83c1f2f2af9e9b2cb1b",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Screening is for colorectal cancer (CRC) in adults 45 and older who are at average risk for the disease. Abbott will exclusively commercialize the test in the U.S. this fall, expanding its CRC screening portfolio with a",
                "category": "company",
                "datetime": 1785139569,
                "headline": "Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Option For Colorectal Cancer, With Freenome Earning $100M Milestone Payment"
              },
              {
                "id": 141028474,
                "url": "https://finnhub.io/api/news?id=9a2687b22714d8cedc636831b2bc62592056cb84c4baeb1b206ee7ea9c167dc4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209914068/image_2209914068.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABT",
                "summary": "Dividend Kings beat SPY in June–July, reclaiming a YTD lead.",
                "category": "company",
                "datetime": 1785093714,
                "headline": "Best Dividend Kings: July 2026"
              },
              {
                "id": 141016843,
                "url": "https://finnhub.io/api/news?id=c8f64aaf8ca368f47b9c370c2b9d1f1ca3af5230aa897d88c88c075e19d32ed7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.",
                "category": "company",
                "datetime": 1784990100,
                "headline": "Why Wall Street Can't Get Enough of This Dividend King"
              },
              {
                "id": 141007741,
                "url": "https://finnhub.io/api/news?id=d7584817bec7c3ef4b0c8862f86610832afabe80d1badde5236e6e6e58315775",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors. Recently, JNJ, GM, and ABT have all raised their outlooks.",
                "category": "company",
                "datetime": 1784906100,
                "headline": "Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher"
              },
              {
                "id": 141005373,
                "url": "https://finnhub.io/api/news?id=b36b031e7ee377bc4138167b006d1828b02fd77c1e500f55b43a05f249614da2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.",
                "category": "company",
                "datetime": 1784895900,
                "headline": "6 Medical-Device Stocks to Buy After a Massive Selloff"
              },
              {
                "id": 141005352,
                "url": "https://finnhub.io/api/news?id=4d73431f2c3617f58fa67a24b0853a1ef831c63ec81636bc814893cef053e08a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.",
                "category": "company",
                "datetime": 1784895812,
                "headline": "Reading Between The Lines Of DHR's Latest Call"
              },
              {
                "id": 141003245,
                "url": "https://finnhub.io/api/news?id=2ebd8eda6820cc2c6f0a825f7bed40d44a97ae7a597344157a7a0eb81e98b72d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.",
                "category": "company",
                "datetime": 1784871000,
                "headline": "Medical-Device Stocks Are in the Bargain Bin. 6 to Buy."
              },
              {
                "id": 140997749,
                "url": "https://finnhub.io/api/news?id=d53c2fad77b0b9e5d6dad30ac140cc93918ffb8a8e510220c597fd23ab667409",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "ISRG's expanding robotic surgery ecosystem and innovation pipeline give it an edge over Abbott for investors seeking stronger long-term MedTech growth.",
                "category": "company",
                "datetime": 1784830140,
                "headline": "ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now?"
              },
              {
                "id": 140990040,
                "url": "https://finnhub.io/api/news?id=7fccb43adc3462ddbaea3052709efe889674ebf1ceae5bca76dd5849170a945b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories earnings put recent stock moves in context Abbott Laboratories (ABT) is back in focus after its latest quarterly earnings, where higher year over year sales came alongside lower net income and earnings per share, sharpening attention on upcoming estimates. See our latest analysis for Abbott Laboratories. After these earnings, Abbott Laboratories' recent rally stands out, with a 7 day share price return of 12.66% and a 30 day share price return of 14.51% contrasting with a...",
                "category": "company",
                "datetime": 1784769014,
                "headline": "Abbott Laboratories (ABT) Earnings Drew Fresh Attention, Is It Still Below Fair Value?"
              },
              {
                "id": 140980996,
                "url": "https://finnhub.io/api/news?id=6402c92c6150025f885e084202c1bab0532dca40ce6b9079c4673f8507f71fed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "WIXOM, Mich., July 22, 2026--Brian Cox joins Rockwell Medical as VP, Quality and Regulatory Compliance, bringing more than 20 years' healthcare experience to the Company.",
                "category": "company",
                "datetime": 1784714400,
                "headline": "Rockwell Medical Advances Quality and Regulatory Leadership"
              },
              {
                "id": 140974912,
                "url": "https://finnhub.io/api/news?id=bbdead80568b813174817288369cedcdbc1558cbe69a3fa5d808987e69a9b82d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "The market is offering a steep discount on this medical device maker, but the price tag comes with a story about slowing growth. Here’s how to read it.",
                "category": "company",
                "datetime": 1784660157,
                "headline": "Why BSX Stock Hands You So Much Cash Right Now"
              },
              {
                "id": 140971473,
                "url": "https://finnhub.io/api/news?id=b128ec3cee87a063d5a49088b82bbd71d52e3598fc8695ab7550deeaf60443c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "JNJ is pruning its portfolio while Abbott just dropped $21 billion to expand into cancer diagnostics, and the two strategies are pulling their stocks in completely opposite directions. Which move looks smarter when you dig into the actual earnings?",
                "category": "company",
                "datetime": 1784646039,
                "headline": "Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories"
              },
              {
                "id": 140971693,
                "url": "https://finnhub.io/api/news?id=a44cd51e74b74d214cb2c38b67dfde3d97fb31250c3bd9176d83a7e1f30be12f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "BSX faces Q2 results with growth expected in key businesses, but lowered full-year guidance, cost pressures and weak stock performance cloud the outlook.",
                "category": "company",
                "datetime": 1784641620,
                "headline": "Boston Scientific's Q2 Earnings Coming Up: Buy, Hold or Sell the Stock?"
              },
              {
                "id": 140971694,
                "url": "https://finnhub.io/api/news?id=6e2b21a1f482923310edb5a75efae7de93dc3eae30084384a0913f2a0c2bbc46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1784638802,
                "headline": "Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140967884,
                "url": "https://finnhub.io/api/news?id=aa3c9497acf88e52a3f7fd6b801778117791298aad033ed5260f6601907d69d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott's diversified healthcare business is one of the main reasons why it remains a reliable dividend stock.",
                "category": "company",
                "datetime": 1784590202,
                "headline": "This Dividend King Could Be One of the Safest Stocks to Own Right Now"
              },
              {
                "id": 140964977,
                "url": "https://finnhub.io/api/news?id=91757da27d905adfa467e3b6268971b5d3137a3598c3aac6b41924b8129c733e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.",
                "category": "company",
                "datetime": 1784562231,
                "headline": "Charles River Laboratories Earnings Preview: What to Expect"
              },
              {
                "id": 140963455,
                "url": "https://finnhub.io/api/news?id=7bb5791ffda9c4a3e860d2e7b480d5bd8bedac536b443f58dcef9e07a707945c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.",
                "category": "company",
                "datetime": 1784558314,
                "headline": "Tempus to buy cancer test-maker Personalis for $1.5B"
              },
              {
                "id": 140940855,
                "url": "https://finnhub.io/api/news?id=31a129fe0260f07c05224d053bcd4eee87605e85893dc76afa78ebbf2cd28d9f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/669315768/image_669315768.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABT",
                "summary": "Semiconductor stocks suffered another violent reversal despite strong results from Taiwan Semiconductor Manufacturing and continued evidence of robust demand for computing infrastructure.",
                "category": "company",
                "datetime": 1784337600,
                "headline": "This Week's Market Wrap: AI Shakeup, Earnings, And Renewed Oil Shock"
              },
              {
                "id": 140940409,
                "url": "https://finnhub.io/api/news?id=06bc2a85ab0843f011d882326328273fe6fc3f0b3921ab9be2d78b44aac39115",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2272099067/image_2272099067.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABT",
                "summary": "Abbott (ABT) buy thesis: diversified growth, EXAS-driven cancer diagnostics upside, attractive valuation & dividend yield, bull-case LTPT $139—read now.",
                "category": "company",
                "datetime": 1784330594,
                "headline": "Abbott: Bear Trap Over, With Richer Return Prospects"
              },
              {
                "id": 140939163,
                "url": "https://finnhub.io/api/news?id=2b7e563ff687d8cc979d3783bccd33f2bf9feb60d528dbd963b372e93e4735fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.",
                "category": "company",
                "datetime": 1784328964,
                "headline": "Abbott Just Showed Its Growth Engine Has More Than One Cylinder"
              },
              {
                "id": 140933087,
                "url": "https://finnhub.io/api/news?id=b598c54d96813d7740cbc8bebfaae0493526087a58537919eaf10b135da45331",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories (ABT) beat Q2 expectations, with growth acceleration in the second half of 2026",
                "category": "company",
                "datetime": 1784300429,
                "headline": "Abbott Laboratories Seen on Track for H2 Growth Acceleration, RBC Says"
              },
              {
                "id": 140945819,
                "url": "https://finnhub.io/api/news?id=39afce453dacda122c0fb0a3aaec8b8a93b1debf518d5f273d1bfc60f10c8425",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Citigroup  analyst Joanne Wuensch   maintains Abbott Laboratories (NYSE:ABT) with a Buy and raises the price target from $108 to $112.",
                "category": "company",
                "datetime": 1784298160,
                "headline": "Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $112"
              },
              {
                "id": 140945820,
                "url": "https://finnhub.io/api/news?id=31c38166d047a49b6a7bf77f79b6a89bb5fc086e05529264bd6a672b0f347bf6",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Piper Sandler  analyst Adam Maeder   reiterates Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $115 to $118.",
                "category": "company",
                "datetime": 1784297374,
                "headline": "Piper Sandler Reiterates Overweight on Abbott Laboratories, Raises Price Target to $118"
              },
              {
                "id": 140933088,
                "url": "https://finnhub.io/api/news?id=83ec2d6328e7b92edab50ec62e7a6e350ba5c5a3931b3f10a35569daf00a30f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care.",
                "category": "company",
                "datetime": 1784296800,
                "headline": "ABT Q2 Earnings Call Flags Stronger Second-Half Setup"
              },
              {
                "id": 140931563,
                "url": "https://finnhub.io/api/news?id=9a8cdb541c3ef9be788480458508c8b7afe3ea54b0f0964b1a39fcf2f3561dab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.",
                "category": "company",
                "datetime": 1784290654,
                "headline": "Can Abbott Stock Deliver on Its Second-Half Growth Promise?"
              },
              {
                "id": 140933089,
                "url": "https://finnhub.io/api/news?id=e2ccfda318db735539c5306060590275d087ec6d3385b7ef6f093b94222978e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "The cyberattack follows Abbott’s recent $21 billion purchase of Exact Sciences. Abbott did not disclose what kind of information was accessed.",
                "category": "company",
                "datetime": 1784287620,
                "headline": "Abbott discloses cyberattack on cancer diagnostics business"
              },
              {
                "id": 140945821,
                "url": "https://finnhub.io/api/news?id=967b4e69091317943ff11065d62e40e74dd11c6a3a1618c0a64086e22cc8a666",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "JP Morgan  analyst Robbie Marcus   maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $110 to $120.",
                "category": "company",
                "datetime": 1784285805,
                "headline": "JP Morgan Maintains Overweight on Abbott Laboratories, Raises Price Target to $120"
              },
              {
                "id": 140931588,
                "url": "https://finnhub.io/api/news?id=33faea986626298ee8200dbcc50b18bc256e86141a90f1a21f0d9c1c6007b135",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Wall Street closed lower on Thursday, dragged down by technology stocks, as investors assessed second-quarter earnings and a batch of economic data.",
                "category": "company",
                "datetime": 1784285520,
                "headline": "Stock Market News for July 17, 2026"
              },
              {
                "id": 140945822,
                "url": "https://finnhub.io/api/news?id=ed41929c3eb812fc7131d58ed0baaf2b6e04a2545f08330ea1e746e60be28be9",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Wells Fargo  analyst Larry Biegelsen   maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $109 to $112.",
                "category": "company",
                "datetime": 1784284090,
                "headline": "Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $112"
              },
              {
                "id": 140945823,
                "url": "https://finnhub.io/api/news?id=7e58d9131d2dd2110996cd389e05f11becd98683d299baa3754a349f09f4e447",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "TD Cowen  analyst Joshua Jennings   reiterates Abbott Laboratories (NYSE:ABT) with a Buy and maintains $115 price target.",
                "category": "company",
                "datetime": 1784282436,
                "headline": "TD Cowen Reiterates Buy on Abbott Laboratories, Maintains $115 Price Target"
              },
              {
                "id": 140932091,
                "url": "https://finnhub.io/api/news?id=b8588bdfb6475cd6accf743645b358b5ad3a8020040f4ac75d0340fb1b4c1e03",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/17/Financial-Analysts.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Abbott Laboratories (NYSE:ABT) reported strong Q2 results, raising its full-year earnings outlook. Analysts have a positive outlook on ABT stock.",
                "category": "company",
                "datetime": 1784281123,
                "headline": "These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results"
              },
              {
                "id": 140932092,
                "url": "https://finnhub.io/api/news?id=c95188d768a8265b53c10a8f86791a848ad26878985977d88f24c04c0e462f57",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Evercore ISI Group  analyst Vijay Kumar   maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $112 to $120.",
                "category": "company",
                "datetime": 1784280866,
                "headline": "Evercore ISI Group Maintains Outperform on Abbott Laboratories, Raises Price Target to $120"
              },
              {
                "id": 140932093,
                "url": "https://finnhub.io/api/news?id=dfefa3bb4e6e6767845dd502ecf3abee31619d7c9069ef3853dcf21a89a4c8b5",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "RBC Capital  analyst Shagun Singh   reiterates Abbott Laboratories (NYSE:ABT) with a Outperform and maintains $130 price target.",
                "category": "company",
                "datetime": 1784278970,
                "headline": "RBC Capital Reiterates Outperform on Abbott Laboratories, Maintains $130 Price Target"
              },
              {
                "id": 140930160,
                "url": "https://finnhub.io/api/news?id=6720d6164b8dfba1ad5181eaf9cf3e1bf4eb430ec8d2d90cba7c11311cb0c944",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "The Morning Bull - US Market Morning Update Friday, Jul, 17 2026 US stock futures are drifting slightly lower this morning, with key index contracts such as the E-mini S&P 500 and Nasdaq-100 off by around 0.1% to 0.4%, as investors weigh tighter financial conditions against mixed global growth signals. A planned 25% US tariff on some Brazilian imports raises questions about costs for companies tied to global trade and agriculture, while US crude stockpiles and the Strategic Petroleum Reserve...",
                "category": "company",
                "datetime": 1784275768,
                "headline": "US Stock Market Today: S&P 500 Futures Dip On Tariff And Energy Cost Worries"
              },
              {
                "id": 140932057,
                "url": "https://finnhub.io/api/news?id=60f53b0f2b42a4752b9620eafb2d9e5c76d750ab7980381c24b63e66e7ab689a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/17/Abbott-Laboratories.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Recent analyst rating changes, top names such as PPG, SAH, ISRG, MMM, OKE, GLDG, ABT, NFLX, TSCO, and SBAC were upgraded or downgraded.",
                "category": "company",
                "datetime": 1784275254,
                "headline": "Abbott To Rally More Than 35%? Here Are 10 Top Analyst Forecasts For Friday"
              },
              {
                "id": 140932095,
                "url": "https://finnhub.io/api/news?id=94ecb167b5fe4e869f331e271a1febc683e2a6f6c762285b6c04048cb7609436",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/17/Intuitive-Surgical-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "ISRG stock drops 11% as Intuitive Surgical beats Q2 estimates but warns insurance changes could slow U.S. procedure growth.",
                "category": "company",
                "datetime": 1784274094,
                "headline": "Why Is Intuitive Surgical Stock Sinking Friday?"
              },
              {
                "id": 140930615,
                "url": "https://finnhub.io/api/news?id=2aa141e01e073ac59d2bd7561aa8d69872942399a72987d0a5b9830169a7c3bf",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2155841301/image_2155841301.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABT",
                "summary": "Abbott Laboratories' strength in Medical Devices business and the recently acquired Exact Sciences should keep driving growth. Read why ABT stock is a buy.",
                "category": "company",
                "datetime": 1784273400,
                "headline": "Abbott Laboratories: Pick Up This Dividend King Deal Now"
              },
              {
                "id": 140932096,
                "url": "https://finnhub.io/api/news?id=6e5d31dcad6141e2190d671982584a10a05b577a370d4b88094bd2f73152ebd1",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "BTIG  analyst Marie Thibault   maintains Abbott Laboratories (NYSE:ABT) with a Buy and raises the price target from $131 to $134.",
                "category": "company",
                "datetime": 1784268812,
                "headline": "BTIG Maintains Buy on Abbott Laboratories, Raises Price Target to $134"
              },
              {
                "id": 140932097,
                "url": "https://finnhub.io/api/news?id=2e7359d6974b402b0c40795020ff5805f074aae474e912ae005a08734a605205",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/17/Fear-and-Greed.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Market sentiment declined as stocks fell, with tech stocks leading the way. UnitedHealth Group and Abbott Laboratories reported strong earnings.",
                "category": "company",
                "datetime": 1784257830,
                "headline": "Nasdaq Tumbles 1.5% Amid Selloff In Chip Stocks: Investor Sentiment Weakens, Greed Index Moves To ‘Fear’ Zone"
              },
              {
                "id": 140928623,
                "url": "https://finnhub.io/api/news?id=5fcc0e4d6ecd549a605904de26828dc2cde172a59e75f941885235dfa08f33c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "A recent acquisition is already bearing fruit.",
                "category": "company",
                "datetime": 1784256033,
                "headline": "Why Abbott Stock Jumped Today"
              },
              {
                "id": 140926062,
                "url": "https://finnhub.io/api/news?id=c763a9b8014830a07a7ce8dbe4769fe8f39eca5ea6a555f9bff0015baf7554d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Memory stocks and semiconductor leaders fell as investor concerns over AI spending resurfaced and U.S.-Iran tensions re-escalated, today, July 16, 2026.",
                "category": "company",
                "datetime": 1784237000,
                "headline": "Stock Market Today, July 16: Micron Plunges as Tech Stocks Extend Sell-Off"
              },
              {
                "id": 140926174,
                "url": "https://finnhub.io/api/news?id=534c87dc30bc88037da24a5ce93963067da47b66a5ba7b868f84d197c9441c0e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories (ABT) reports robust sales growth and raises full-year EPS guidance, driven by strong performance in Nutrition, Medical Devices, and Emerging Markets.",
                "category": "company",
                "datetime": 1784235623,
                "headline": "Abbott Laboratories (ABT) Q2 2026 Earnings Call Highlights: Strong Growth in Key Segments and ..."
              },
              {
                "id": 140926015,
                "url": "https://finnhub.io/api/news?id=eb0485d7bdb461bc6a85eaa874136281a55721fe0ca632c7f0b439cf637098e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "(Updates with closing levels throughout the story.) Wall Street's stock indexes fell Thursday aft",
                "category": "company",
                "datetime": 1784234832,
                "headline": "Update: Wall Street Snaps Two-Day Advance as Chip-Related Stocks Slump"
              },
              {
                "id": 140926145,
                "url": "https://finnhub.io/api/news?id=d43782cae5fe933bb6d4af253e444fe1c15e73da03e4138794945c3b2d46b713",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "US equity indexes closed lower on Thursday amid a sell-off in technology stocks, and Iran threatened",
                "category": "company",
                "datetime": 1784233456,
                "headline": "US Equity Markets End Lower Amid Tech Sell-Off, Iran's Threat to Block Red Sea"
              },
              {
                "id": 140926177,
                "url": "https://finnhub.io/api/news?id=027d3633509cd297ac4a3e4973aac87bc8d81786e557a57dd25ed60dca1110fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories has reported its second-quarter 2026 results, with sales rising to US$12.59 billion from US$11.14 billion a year earlier, while net income fell to US$928 million and diluted EPS from continuing operations declined to US$0.53. Despite lower net income, Abbott delivered better-than-expected adjusted earnings, lifted its full-year 2026 adjusted EPS guidance, and highlighted strong growth in higher-margin Medical Devices and Cancer Diagnostics, signalling a continued shift in...",
                "category": "company",
                "datetime": 1784232877,
                "headline": "Abbott (ABT) Lifts 2026 EPS Outlook Amid Business Mix Shift Toward Devices and Diagnostics"
              },
              {
                "id": 140926178,
                "url": "https://finnhub.io/api/news?id=a0bfea10890842e5673531dda292cb532f2b01eceacde9991045aaf5cbc8ea40",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott stock jumped early Thursday on better-than-expected second-quarter metrics. The company also raised its 2026 profit view.",
                "category": "company",
                "datetime": 1784232654,
                "headline": "Abbott, Up 11%, Strikes Three-Month High After Boosting 2026 Profit Outlook"
              },
              {
                "id": 140923897,
                "url": "https://finnhub.io/api/news?id=eec3217290a10ec063680087ba18a7cce53e9971ec864a5f4584bc7b86e17a0c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "ABT",
                "summary": "Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1784228701,
                "headline": "Explore the top gainers and losers within the S&P500 index in today's session."
              },
              {
                "id": 140924356,
                "url": "https://finnhub.io/api/news?id=4cf4123c77645396152af3dffe89ed9d8152bee3fb8732cc5325fb9e859f0728",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "US benchmark equity indexes were lower intraday amid a sell-off in certain chip-related stocks as in",
                "category": "company",
                "datetime": 1784225083,
                "headline": "Chip Stocks Weigh on Equities Intraday; Netflix Earnings on Deck"
              },
              {
                "id": 140934549,
                "url": "https://finnhub.io/api/news?id=d51773e7e9b1757f976327eeb3938c960072f147dd71a68a016963a670305473",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott's Q2 results show solid organic growth, better-than-expected margins, and improved earnings guidance, easing concerns over the Exact Sciences acquisition and boosting ABT shares.",
                "category": "company",
                "datetime": 1784223900,
                "headline": "Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street"
              },
              {
                "id": 140919567,
                "url": "https://finnhub.io/api/news?id=5b5cac05d3caf4d6f487a5a4f455d81648644f9d99ba884c8538700d1a56d35e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Stock Market Today: The Nasdaq composite dropped Thursday as Sandisk and SK Hynix plunged. TSMC sold off on earnings.",
                "category": "company",
                "datetime": 1784223691,
                "headline": "Stock Market Today: Nasdaq Slides As Sandisk, SK Hynix Plunge; Nvidia Chipmaker TSMC Tumbles (Live Coverage)"
              },
              {
                "id": 140922068,
                "url": "https://finnhub.io/api/news?id=965c01c9b245361bdf977d67366bbe7163bdbe9e627ad9446793cc5a3843527d",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "ABT",
                "summary": "Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.",
                "category": "company",
                "datetime": 1784221500,
                "headline": "Unusual volume S&P500 stocks in Thursday's session"
              },
              {
                "id": 140921837,
                "url": "https://finnhub.io/api/news?id=192e750e79a3e75ab0d468b53d4de78fd222cc21fdcb5c63cb9253fb73f4301d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "ABT",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday.",
                "category": "company",
                "datetime": 1784219700,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 140922750,
                "url": "https://finnhub.io/api/news?id=970545d24c81aa031b0996115528edd0b830794863d4491b8bc5a161532c86c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories (NYSE:ABT) shares rose nearly 11% on Thursday after the healthcare company reported second quarter 2026 results that topped Wall Street expectations and raised its full-year adjusted earnings guidance. The company posted adjusted diluted earnings per share of $1.31 for the...",
                "category": "company",
                "datetime": 1784218980,
                "headline": "Abbott Laboratories shares jump as earnings beat estimates and company raises 2026 outlook"
              },
              {
                "id": 140922751,
                "url": "https://finnhub.io/api/news?id=064695c2c7c73e8c795a57647a68b4874cbf622ad91f18be92ec15c915686b53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness.",
                "category": "company",
                "datetime": 1784217000,
                "headline": "Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market"
              },
              {
                "id": 140921002,
                "url": "https://finnhub.io/api/news?id=5cbca686c587dddbb0e54de0ea21ea049d798da3c19f6986bbf30718a4f932e5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "The S&P 500 and Nasdaq Composite were down in late-morning trading Thursday, while the Dow Jones Ind",
                "category": "company",
                "datetime": 1784216517,
                "headline": "Top Midday Stories: Taiwan Semiconductor Q2 Earnings Top Estimates, Increases Capex; UnitedHealth Raises Full-Year Guidance"
              },
              {
                "id": 140920993,
                "url": "https://finnhub.io/api/news?id=53e72dfdc0a3fab7afbb6d59f65360596204973489784cf79e3fc6f96c90d9fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters. The company reaffirmed its full-year compara",
                "category": "company",
                "datetime": 1784214288,
                "headline": "Abbott Laboratories Q2 Earnings Call Highlights"
              },
              {
                "id": 140920973,
                "url": "https://finnhub.io/api/news?id=383c8a910d0b53a4d210ac7d5f3ecafa0dbf367b7fec681eb1bd02c4862d419b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.",
                "category": "company",
                "datetime": 1784212620,
                "headline": "Why Abbott Stock Is Having Its Best Day in 24 Years"
              },
              {
                "id": 140921080,
                "url": "https://finnhub.io/api/news?id=2fcb502ae22e32201925af147d788347e32c5ef4febd67a3b54fe73f90aaa920",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories (ABT) lifted its full-year earnings outlook on Thursday as the healthcare firm r",
                "category": "company",
                "datetime": 1784212339,
                "headline": "Abbott Laboratories Raises Full-Year Earnings Guidance as Second-Quarter Results Top Views"
              },
              {
                "id": 140921081,
                "url": "https://finnhub.io/api/news?id=c301e2dccc5dd3c9f512c60cfaa45e5249b9764c41a798d54112d20b11eacd4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott stock jumped early Thursday on better-than-expected second-quarter metrics. The company also raised its 2026 profit view.",
                "category": "company",
                "datetime": 1784211724,
                "headline": "Abbott, Up 14%, Strikes Three-Month High After Boosting 2026 Profit Outlook"
              },
              {
                "id": 140920951,
                "url": "https://finnhub.io/api/news?id=4edc50fb0c0b3163368a3ac06c10ca151d88a91c32421f42358d93e3f325254f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "AMD, Dell, Intel, and Micron shares fall as Wall Street questions how long the AI spending boom can last.",
                "category": "company",
                "datetime": 1784211300,
                "headline": "Sandisk, Micron, TSMC, UnitedHealth, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140920976,
                "url": "https://finnhub.io/api/news?id=76bc23d4d790ded7e25ac854371641c9f43064d0b6f2a5978ce3830dc769912b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.",
                "category": "company",
                "datetime": 1784210345,
                "headline": "Why Abbott Stock Is Reimagining Its Future"
              },
              {
                "id": 140921084,
                "url": "https://finnhub.io/api/news?id=38e4ed26648e2d6baa3ebe3a3cba15aae63eb362c42966479e6a0db4a4c46d6c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
                "category": "company",
                "datetime": 1784208604,
                "headline": "Here's What Key Metrics Tell Us About Abbott (ABT) Q2 Earnings"
              },
              {
                "id": 140919864,
                "url": "https://finnhub.io/api/news?id=09ee70bec18ed29dbf6945e80ccc48e64d23faf4f8b9889ee5f973d62001dc07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "The healthcare company posted adjusted earnings of $1.31 a share in the second quarter, topping Wall Street's estimate of $1.28",
                "category": "company",
                "datetime": 1784207989,
                "headline": "Abbott Q2 2026 earnings beat, raises full-year profit guidance"
              },
              {
                "id": 140922070,
                "url": "https://finnhub.io/api/news?id=0f1dc2d14383b5fd13e05e0bb92c9a509efe967aec35499e2b0419579b82a3f5",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "ABT",
                "summary": "Abbott Laboratories (ABT) Q2 2026 Earnings Call July 16, 2026 9:00 AM EDTCompany ParticipantsMichael Comilla - Vice President of Investor Relations.Robert...",
                "category": "company",
                "datetime": 1784207777,
                "headline": "Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 140919865,
                "url": "https://finnhub.io/api/news?id=86e56b5c45c793b76ead83bad9c72a5d8f0912b5fd92584df58ee7c2432bdcf4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories stock has fallen sharply over the past year, yet both an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and traditional market multiples currently point to the shares trading at a discount. The share price is down about 30.7% over the past year, which has pushed investor sentiment lower while opening a potential valuation gap. Progress in colorectal cancer diagnostics and partnerships in continuous glucose monitoring can support long term cash...",
                "category": "company",
                "datetime": 1784207588,
                "headline": "Is Abbott Laboratories (ABT) Below Fair Value After Its 31% Fall?"
              },
              {
                "id": 140932098,
                "url": "https://finnhub.io/api/news?id=2c0debfcbad745e90d5003781e17b309c8965d47cc01361a505fb4452873db96",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Abbott-Laboratories.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Abbott (ABT) stock jumps 12% after beating Q2 2026 earnings and revenue estimates and raising its full-year profit outlook. Read more.",
                "category": "company",
                "datetime": 1784207432,
                "headline": "Abbott Brushes Off Procedure Volume Concerns, Lifts Outlook"
              },
              {
                "id": 140922278,
                "url": "https://finnhub.io/api/news?id=b504a98e7ae20db43681c957359e73da60aa3cc75f9fd87dee10f5fb4d8fa1b8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Digital-Gold-Price-Stock-Market-Trading-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "A semiconductor selloff sank the Nasdaq 100 more than 1% while UnitedHealth's blowout quarter lifted the Dow.",
                "category": "company",
                "datetime": 1784207165,
                "headline": "Chip Selloff Drags Nasdaq 100, Gold Sinks Below $4,000: Stock Market Today"
              },
              {
                "id": 140919866,
                "url": "https://finnhub.io/api/news?id=509f84617596f0b1c69298e65dcd588faeea5e47e21a78202a81b964f2da234e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 13% year on year to $12.59 billion. Its non-GAAP profit of $1.31 per share was 2.6% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1784206827,
                "headline": "Abbott Laboratories (NYSE:ABT) Surprises With Q2 CY2026 Sales"
              },
              {
                "id": 140919867,
                "url": "https://finnhub.io/api/news?id=7d82e7c2f81af35d04a09a8ed46a4ae6c34bdb05d9c92ee909ea4b376ab38997",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott stock jumped early Thursday on better-than-expected second-quarter metrics. The company also raised its 2026 profit view.",
                "category": "company",
                "datetime": 1784206523,
                "headline": "Abbott Bounds Higher After Hiking 2026 Profit View On Second-Quarter Beat"
              },
              {
                "id": 140919868,
                "url": "https://finnhub.io/api/news?id=7ec85e87071274edcfe5944dc3dfafcedf63ced292b7a5b613e90804ceba9ea5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories (NYSE:ABT) delivered stronger-than-expected second-quarter results and increased its full-year earnings guidance, sending its shares about 2. 5% higher in premarket trading.",
                "category": "company",
                "datetime": 1784205790,
                "headline": "Abbott raises 2026 earnings outlook after second-quarter results beat expectations (ABT)"
              },
              {
                "id": 140919869,
                "url": "https://finnhub.io/api/news?id=a22b0b621d9ee69d6c8c6dcdc7a7a1f11e2fab859a3b65790998c76992f4d2cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott (ABT) delivered earnings and revenue surprises of +2.34% and +0.91%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1784205602,
                "headline": "Abbott (ABT) Q2 Earnings and Revenues Top Estimates"
              },
              {
                "id": 140922752,
                "url": "https://finnhub.io/api/news?id=220de3a11a738dc153d4894fd47dc2e122b2fc094b757303a1bb9a3836d0c8ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "The Exact Sciences acquisition, which closed in March, fueled more than 40% growth in Abbott’s diagnostics sales in the second quarter.",
                "category": "company",
                "datetime": 1784205450,
                "headline": "Abbott reports diagnostics growth since $21B Exact Sciences buy"
              },
              {
                "id": 140919291,
                "url": "https://finnhub.io/api/news?id=195f8e2045a457bd41c82088ca85aafdc16620b26b540f6e0008b4d2a9b08064",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "ABT",
                "summary": "The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.",
                "category": "company",
                "datetime": 1784205300,
                "headline": "What's going on in today's pre-market session: S&P500 movers"
              },
              {
                "id": 140919183,
                "url": "https://finnhub.io/api/news?id=19849ac679df3167b2c369978d8db01f62341cdae91c4b1f15c75923f8b77cb4",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp",
                "source": "ChartMill",
                "related": "ABT",
                "summary": "Abbott Labs Q2 2026 earnings met expectations, slightly beating EPS estimates. The company raised its full-year guidance, boosting investor confidence and driving pre-market gains over 3%.",
                "category": "company",
                "datetime": 1784204415,
                "headline": "Abbott Laboratories NYSE:ABT Rises on In-Line Q2 and Raised Guidance"
              },
              {
                "id": 140919870,
                "url": "https://finnhub.io/api/news?id=644a211551a266877c024f175c95790839fb596fc414e76ce835604f5de218ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Investing.com -- Abbott (NYSE:ABT) shares are trading higher premarket on Thursday after the company reported second-quarter earnings, topping consensus expectations and raising its full-year earnings guidance.",
                "category": "company",
                "datetime": 1784203822,
                "headline": "Abbott beats second-quarter estimates, raises 2026 guidance"
              },
              {
                "id": 140919722,
                "url": "https://finnhub.io/api/news?id=bd3a772633121acf0452f10ab368b69a562e2c64a485ce99d79a2ec01db57828",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.",
                "category": "company",
                "datetime": 1784203500,
                "headline": "Why Abbott Earnings Are Sending the Stock Higher"
              },
              {
                "id": 140922250,
                "url": "https://finnhub.io/api/news?id=04cc454e8478bb50f040a2287435d1d39491ae9e6a5439dac7a26130e0abb7d8",
                "image": "https://image.cnbcfm.com/api/v1/image/107357257-1704980167454-gettyimages-1923334243-em025859_2024011024645207.jpeg?v=1752853252&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABT",
                "summary": "These are the stocks posting the largest moves in midday trading.",
                "category": "company",
                "datetime": 1784203428,
                "headline": "Stocks making the biggest moves midday: Manpower, Abbott, UnitedHealth, TSMC & more"
              },
              {
                "id": 140920920,
                "url": "https://finnhub.io/api/news?id=19bf65b45f39954e551257debea7ac82f53fa593583892062a74d662bf2a32d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Oil prices traded just below $80 a barrel, despite further escalation in the Middle East",
                "category": "company",
                "datetime": 1784203260,
                "headline": "Nasdaq dragged by chip sell-off, Abbott, UnitedHealth lead risers"
              },
              {
                "id": 140919007,
                "url": "https://finnhub.io/api/news?id=771d9664ea62680d615917594299022b078b00aebe2e1d6d1943bef81bc09572",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "US equity markets were mostly tracking in the red before the opening bell Thursday as traders await",
                "category": "company",
                "datetime": 1784202919,
                "headline": "Stocks Mostly Down Pre-Bell as Investors Await More Earnings, Retail Sales Data"
              },
              {
                "id": 140920827,
                "url": "https://finnhub.io/api/news?id=7507f2f916e48b361c357533b4ddd02aa08311f1a331957fd868880aeecf67ff",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181343095/image_1181343095.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABT",
                "summary": "Abbott Laboratories surged 14% after strong Q2 earnings and raised FY2026 guidance—see valuation, growth drivers and hold call. Click for this ABT stock update now.",
                "category": "company",
                "datetime": 1784202382,
                "headline": "Abbott Laboratories: Double Beat And Raise Surprises The Street (Rating Upgrade)"
              },
              {
                "id": 140918908,
                "url": "https://finnhub.io/api/news?id=729ef6fed40a9f081dd4f2ef6b802368e53e3c0bf411122055a0f7c3b853f713",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Wall Street still prices Abbott like a slow-and-steady dividend stalwart, but a pair of massive strategic moves beneath the surface suggests that framing may be costing investors a significant opportunity.",
                "category": "company",
                "datetime": 1784202001,
                "headline": "What Investors Don’t Understand About Abbott Laboratories"
              },
              {
                "id": 140918909,
                "url": "https://finnhub.io/api/news?id=12eb1ebcadb4982299e0fd35556d675373424cd87ede8fd57c4ae663b6b10ec3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2026.",
                "category": "company",
                "datetime": 1784201400,
                "headline": "Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance"
              },
              {
                "id": 140921583,
                "url": "https://finnhub.io/api/news?id=5f91580b8e89d0e1c5ba907acae578ba5dc2f4f87a7760ea8500a5ce4e01bd6c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Abbott-Laboratories.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Abbott Laboratories stock surged over 13% Thursday after second-quarter earnings topped estimates and the company raised its full-year profit outlook.",
                "category": "company",
                "datetime": 1784198735,
                "headline": "Abbott Stock's Best Day Ever: +13.6% On Earnings Beat, Guidance Raise"
              },
              {
                "id": 140921584,
                "url": "https://finnhub.io/api/news?id=2bba6de72fe375f9ca1b7f4f8f76dde6816551045018b2c89d9e8e747e78020e",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Abbott Laboratories (NYSE:ABT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below.\nBenzinga APIs provide real-time access to earnings call transcripts",
                "category": "company",
                "datetime": 1784197650,
                "headline": "Abbott Laboratories Reports Q2 2026 Results: Full Earnings Call Transcript"
              },
              {
                "id": 140921585,
                "url": "https://finnhub.io/api/news?id=9def745995e7542ecf022db8e844647659061ef8e8950b3dcac697d0fb475494",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Abbott-Laboratories.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "\nU.S. stocks mixed, Nasdaq falls 150 points. Abbott Labs beats Q2 estimates and raises guidance, stock jumps 12.1%. Other big gainers include ATAI, MAN, DSGR, CDNA, MAAS, HELP, RHI, SMG, FWRD, UNH, JBHT.",
                "category": "company",
                "datetime": 1784196687,
                "headline": "Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday"
              },
              {
                "id": 140921586,
                "url": "https://finnhub.io/api/news?id=ffb9a175927dc6a491e86dd9b4db36b07c1d81e3a3ac2b179d195eba7da5e523",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Abbott Laboratories (NYSE:ABT) is looking for Q3 Adj EPS of $1.38-$1.46 vs $1.42 analyst estimate..",
                "category": "company",
                "datetime": 1784187115,
                "headline": "Abbott Laboratories Sees Q3 Adj EPS $1.38-$1.46 vs $1.42 Est"
              },
              {
                "id": 140921587,
                "url": "https://finnhub.io/api/news?id=32fb24c4f43351f2624bf0a23704ca7d4b8824a59d7461662c63d3bb3071e2d7",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Abbott Laboratories (NYSE:ABT) raises FY2026 Adj EPS guidance from $5.38-$5.58 to $5.45-$5.60 vs $5.49 analyst estimate..",
                "category": "company",
                "datetime": 1784187070,
                "headline": "Abbott Laboratories Raises FY2026 Adj EPS Guidance from $5.38-$5.58 to $5.45-$5.60 vs $5.49 Est"
              },
              {
                "id": 140920453,
                "url": "https://finnhub.io/api/news?id=2706d3fd5e403e9e1f0e750e21e56b176ac8b98228a529df669383d5480003dc",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/earnings_scheduled_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Companies Reporting Before The Bell\n• U.S. Bancorp (NYSE:USB) is likely to report quarterly earnings at $1.27 per share on revenue of $7.59 billion. \n• New Horizon Aircraft (NASDAQ:HOVR) is expected to report earnings",
                "category": "company",
                "datetime": 1784185876,
                "headline": "Earnings Scheduled For July 16, 2026"
              },
              {
                "id": 140919831,
                "url": "https://finnhub.io/api/news?id=02e5cfafab2f230d5851017b6cff88c1f0834bd1d7d075333cebf26083be368a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Computer chipmakers and other winners of the artificial-intelligence boom are swinging lower again on Thursday and dragging stock markets down worldwide.  Oil prices, meanwhile, continue to climb because of the war with Iran.  AI winners like Micron Technology led the way lower, and the maker of computer memory fell 3.2%.",
                "category": "company",
                "datetime": 1784178833,
                "headline": "AI stocks slump again, while oil prices keep climbing"
              },
              {
                "id": 140921589,
                "url": "https://finnhub.io/api/news?id=d0ad5103be2052ab2a5a6eb656387ef61a23257581fa8d6f4622d46faf527de2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/UnitedHealth-Slumps-As-Investors-Pivot-T.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "US stock futures mixed, investors to focus on UnitedHealth, J B Hunt, Abbott, TSMC and GE Aerospace earnings. TSM beats expectations.",
                "category": "company",
                "datetime": 1784171904,
                "headline": "UnitedHealth, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursday"
              },
              {
                "id": 140920414,
                "url": "https://finnhub.io/api/news?id=e8691e8f49c485505eb6d73a33629b4f9f9ff1316fc8087d2739a98b7174297e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Fear-and-Greed.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "U.S. stocks gain, led by Amazon and Alphabet. Apple hits record high. Aehr Test Systems and Morgan Stanley report strong earnings. PPI data cools inflation fears.",
                "category": "company",
                "datetime": 1784171830,
                "headline": "Dow Jumps 150 Points Following Producer Inflation Data: Investor Sentiment Improves, Fear & Greed Index In ‘Neutral’ Zone"
              },
              {
                "id": 140922163,
                "url": "https://finnhub.io/api/news?id=b9034c93deb02bb4e5b29f74682d77ab5a98ab2992f96e8bfb34911049bf1d19",
                "image": "https://image.cnbcfm.com/api/v1/image/108322609-1781626040979-Traders-Photo-20260616-KK-PRESS-010.jpg?v=1781626133&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABT",
                "summary": "Stocks closed higher across the board Wednesday as traders digested more data showing inflation is easing. Major tech stocks like Amazon and Alphabet also rose.",
                "category": "company",
                "datetime": 1784138263,
                "headline": "Thursday's big stock stories: What’s likely to move the market in the next trading session"
              },
              {
                "id": 140911296,
                "url": "https://finnhub.io/api/news?id=aee602b293e01bdae62f2d6674938ab67845e74bf45b3536a1bd3aa55fdad064",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.",
                "category": "company",
                "datetime": 1784134793,
                "headline": "J&J Slipped On Its Report; Why It Bodes Well For Intuitive, Abbott, Others"
              },
              {
                "id": 140911407,
                "url": "https://finnhub.io/api/news?id=5092f38ba748d794f8bf6438843d78c93d7d6967ccb5be76ad39f133c381655a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "ABT is banking on emerging-market pharmaceutical growth and innovation in Nutrition, but macro pressures and currency swings remain key challenges.",
                "category": "company",
                "datetime": 1784131500,
                "headline": "Reasons to Retain Abbott Stock in Your Portfolio for Now"
              },
              {
                "id": 140913208,
                "url": "https://finnhub.io/api/news?id=a2c4efc0a1dfea40fc5f46748d8ab33e2f1b0a9bce154f011ebe42fe9163b783",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/15/Stock-Market-Graph-Trading-Analysis-Inve.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Earnings focus on Thurs, Benzinga-selected slate: industrial engines, logistics real estate, streaming, medical devices. Options market offers snapshot of volatility. UnitedHealth Group Inc. (NYSE:UNH) is the marquee name. Prologis, Inc. (NYSE:PLD) reports before opening bell, GE Aerospace (NYSE:GE) reports after bell.",
                "category": "company",
                "datetime": 1784129465,
                "headline": "Netflix's Q3 Earnings Report Could Lead to $21.5 Billion Swing in Market Value"
              },
              {
                "id": 140909591,
                "url": "https://finnhub.io/api/news?id=7f9bf71fadecdd9a92d2d7c8741a7205f9c570edb10edb3efdbbed51786a82c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Johnson & Johnson’s  second-quarter earnings were met with a shrug on Wall Street, but one of the drugmaker’s top executives insists the most powerful growth drivers are just starting to pick up speed.  J&J on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated.  “I think the second quarter was just an affirmation of the first quarter,” Chief Financial Officer Joe Wolk said in an interview with Barron’s. “Our pharmaceutical unit continues to thrive, surpassing $16 billion in sales for the first time ever in the company’s history.”",
                "category": "company",
                "datetime": 1784128500,
                "headline": "Johnson & Johnson CFO Says This Drug Is Outperforming ‘Almost Any Launch’ in Recent Memory"
              },
              {
                "id": 140911408,
                "url": "https://finnhub.io/api/news?id=6468753b782ff4428ac6fa008bf9096f5550b9de9ffc6fafe288c3d0bf5d0962",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Jorge Garces, who joined Abbott to oversee scientific strategy for cancer diagnostics after it acquired Exact Sciences, discusses the future of the field.",
                "category": "company",
                "datetime": 1784116980,
                "headline": "Abbott’s cancer diagnostics vision: ‘There’s always a hunger to make these tests better’"
              },
              {
                "id": 140901598,
                "url": "https://finnhub.io/api/news?id=1c30ec9fc5eaa65b249de9077cf426329d566c616ac5f9591f0e7f9ba8098349",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Intuitive Surgical stock tumbled Tuesday after HCA Healthcare trimmed its full-year earnings outlook, noting a drop in surgeries.",
                "category": "company",
                "datetime": 1784058057,
                "headline": "Why This Group Of Medical Giants, Including Intuitive Surgical, Just Took A Tumble"
              },
              {
                "id": 140898225,
                "url": "https://finnhub.io/api/news?id=b650bd0404d07d15723345af5bfd6859bfe7fe9df9d504ab0885e15a63cbfe95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.",
                "category": "company",
                "datetime": 1784036040,
                "headline": "Abbott's Q2 Earnings on Deck: How Should You Play the Stock Now?"
              },
              {
                "id": 140091407,
                "url": "https://finnhub.io/api/news?id=4f3bae5f1a4e13b081552f7770afdce76cba0f5763322ce7524be732ab5f910f",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "",
                "category": "company",
                "datetime": 1784034450,
                "headline": "Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation"
              },
              {
                "id": 140895068,
                "url": "https://finnhub.io/api/news?id=6ad7b96323c88f2e73436d2e68ee60c850fe98f5ea198ccbc527701c6f3eb6ad",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1478156131/image_1478156131.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABT",
                "summary": "SCHD has returned just under 2% in the past month, outperforming the S&P 500 ETF SPY by almost 100 bps. Read more on SCHD's holdings here.",
                "category": "company",
                "datetime": 1784006292,
                "headline": "The Hidden Winners Inside SCHD - July 2026"
              },
              {
                "id": 140894196,
                "url": "https://finnhub.io/api/news?id=ce54dcd3213fe39a575ae9d8dfca8d8c3c8ab18a053b31d59baa95ee32ca2d22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Blood Glucose Monitoring System Market size & share revenue was valued at approximately USD 16.8 Billion in 2025 and is expected to reach USD 18.3 Billion in 2026 and is expected to reach around USD 39.4 Billion by 2035, at a CAGR of 8.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Insulet Corporati",
                "category": "company",
                "datetime": 1784003400,
                "headline": "Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights"
              },
              {
                "id": 140891229,
                "url": "https://finnhub.io/api/news?id=0a023d46a31322023b8459e9579bf4e88d08889b900df99a7955bcccc5f83e6b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott is down nearly 23% this year while Pfizer dangles a 7% yield, and both just beat Q1 estimates. One of these discounts is a genuine buying opportunity and the other is a slow-moving trap waiting to spring.",
                "category": "company",
                "datetime": 1783975629,
                "headline": "Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?"
              },
              {
                "id": 140887009,
                "url": "https://finnhub.io/api/news?id=40afb5706fc7aa07db5244ad6314137dbf6f895560ea8d63e10defddd8af1029",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.",
                "category": "company",
                "datetime": 1783948505,
                "headline": "Unlocking Q2 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics"
              },
              {
                "id": 140888490,
                "url": "https://finnhub.io/api/news?id=4e9a1c328a45b5bc4c7c6f53eab6405aa02a9a80a4df9234ce7f9349a930bc5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.",
                "category": "company",
                "datetime": 1783941727,
                "headline": "Freenome colorectal cancer test data improve on earlier results"
              },
              {
                "id": 140884451,
                "url": "https://finnhub.io/api/news?id=c572dcc2d50756b967a34ab9d00ff3969f7f47f9cc2937ddd6b467ff69b18ea2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories (NYSE:ABT) is one of the Best Monopoly Stocks to Buy According to Hedge Funds. On June 30, Baird initiated coverage on the company’s stock with an “Outperform” rating, setting a price objective of $121.00. The firm sees Abbott Laboratories (NYSE:ABT)’s portfolio as delivering steady top-line and earnings growth over the upcoming several years. As per […]",
                "category": "company",
                "datetime": 1783934505,
                "headline": "Baird Initiates Coverage on Abbott Laboratories (ABT) Stock with Outperform Rating"
              },
              {
                "id": 140874439,
                "url": "https://finnhub.io/api/news?id=ab8c8d96a3a2023f92cd86fe3cef04db819694c040f7fa14139add667b77bf47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "In July 2026, Tandem Diabetes Care announced that its t:slim X2 insulin pump with Control-IQ+ technology is now compatible with Abbott’s FreeStyle Libre 3 Plus CGM in the UK, Switzerland, Sweden, Finland, and Italy, expanding CGM choice for pump users and enabling 15-day sensors with minute-by-minute glucose data. This integration strengthens Tandem’s ecosystem by pairing its advanced AutoBolus-enabled AID algorithm with one of Europe’s most widely used CGM platforms, potentially broadening...",
                "category": "company",
                "datetime": 1783818432,
                "headline": "Does Libre 3 Plus Integration Expand Tandem’s Interoperability Edge And Bull Case For TNDM?"
              },
              {
                "id": 140874399,
                "url": "https://finnhub.io/api/news?id=bd3b54002ab4b2611e2f90fc6668b5c27052c504d0a61410bc750feee435ee0b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak.",
                "category": "company",
                "datetime": 1783816500,
                "headline": "AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty"
              },
              {
                "id": 140871585,
                "url": "https://finnhub.io/api/news?id=dd79a210b72ec6a7b7f17608596f44d1a1428a0189e4d47e2cb76e5041e2722f",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "ABT",
                "summary": "Wall Street Week Ahead: key earnings (JPM, BAC, GS), CPI/PPI, retail sales, IPOs & dividends—get timely stock market updates and plan trades.",
                "category": "company",
                "datetime": 1783767600,
                "headline": "Banking Heavyweights To Kick Off Earnings Next Week"
              },
              {
                "id": 140869947,
                "url": "https://finnhub.io/api/news?id=85f5bbcc56820d75ff3d83dbef24ce950c662cf8f20e040aa531137d25415673",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Tandem Diabetes Care (TNDM) is back in focus after announcing that its t:slim X2 insulin pump with Control-IQ+ technology now connects with Abbott’s FreeStyle Libre 3 Plus CGM across five European countries. See our latest analysis for Tandem Diabetes Care. The Abbott tie up comes as Tandem Diabetes Care’s 1 year total shareholder return is down 1.15%, while the share price has fallen 28.49% year to date to $15.41. This suggests recent momentum has faded despite the product expansion...",
                "category": "company",
                "datetime": 1783760961,
                "headline": "Is Tandem Diabetes Care (TNDM) Undervalued Following Its Abbott Libre 3 Plus Expansion?"
              },
              {
                "id": 140865222,
                "url": "https://finnhub.io/api/news?id=791ae73bf704bfbce3afcab86b035b2ad22dfe971fad0cee9e12627a57b6f74f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott and Danaher both reported Q1 2026 results, but the businesses underneath those numbers point in opposite directions, and choosing the wrong one right now costs more than just a few percentage points of return.",
                "category": "company",
                "datetime": 1783707528,
                "headline": "Abbott Labs Vs. Danaher: Abbott’s Everyday Products Beat Danaher’s Slumping Biotech Equipment"
              },
              {
                "id": 140866137,
                "url": "https://finnhub.io/api/news?id=3f13457ebf4a4219407fc1e247b73e139d9eff63c7d44cc4326643ba6b21d03b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABT",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the latest list here.",
                "category": "company",
                "datetime": 1783706132,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 12"
              },
              {
                "id": 140861684,
                "url": "https://finnhub.io/api/news?id=2d80c78d867e1b8c4361f0f878b8dcf7d65ca471b42d1cd018154a011edfcc86",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "The company’s business grew at a healthy clip, yet its stock price went sideways and its valuation fell. Something has to give.",
                "category": "company",
                "datetime": 1783685317,
                "headline": "DXCM Grew. The Stock Did Not. Someone Is Wrong"
              },
              {
                "id": 140860151,
                "url": "https://finnhub.io/api/news?id=d4946c4508ab40c2456975303adae442a5a4daa65f616a1b0d59702ebf3b420a",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "ABT",
                "summary": "Abbott Laboratories offers a reliable 2.64% dividend yield backed by strong profitability, a 10-year growth history, and a reasonable P/E ratio of 18.12, making it a solid passive income pick.",
                "category": "company",
                "datetime": 1783678833,
                "headline": "Dividend Powerhouse: Abbott Laboratories (NYSE:ABT) Passes the Test for Sustainable Income"
              },
              {
                "id": 140859936,
                "url": "https://finnhub.io/api/news?id=83e73494e945e8288e791f886011a1f063c90acb330b461d1f051a8e62a69c87",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "The global advanced therapeutics market, focused on aging and wellness, is set to grow from $154.89 billion in 2024 to $275.35 billion by 2035, at a CAGR of 5.51%. This market, covering nutritional formulations and functional bioactives, is driven by aging populations, chronic conditions, and a shift toward preventive health. North America leads the market due to its robust healthcare ecosystem and consumer awareness. Key segments in the market include functional nutrition, energy and active agi",
                "category": "company",
                "datetime": 1783670520,
                "headline": "Advanced Therapeutics (Aging and Wellness) Market Report Now Available; 146-Page Study Profiling Abbott, Nestlé, Herbalife, Amway & 11 Others, Covering Sports, Functional & Therapeutic Nutrition"
              },
              {
                "id": 140852127,
                "url": "https://finnhub.io/api/news?id=3dc0ae22f59ecc076a1a15b91bdc68fa65b5f68b674058d014aa38fddece5920",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "If you hold shares in this medical device maker, you are already carrying the full weight of a sizable potential swing that the market is pricing for the year ahead.",
                "category": "company",
                "datetime": 1783604422,
                "headline": "The Wide Chasm Priced Into Boston Scientific Stock"
              },
              {
                "id": 140852259,
                "url": "https://finnhub.io/api/news?id=d9d509c3d2f96ae3b116903a57587fe22f1ed896b2a7e019b92e3396686ef8aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
                "category": "company",
                "datetime": 1783603802,
                "headline": "Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet"
              },
              {
                "id": 140845618,
                "url": "https://finnhub.io/api/news?id=a88f675a10eacf733ae13992621b5bb45942e9915886ecb5c472a50a1e8262a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitoring (CBGM) platform as it moves towards commercialization. This adds to the company’s three CBGM patents issued in 2025 and includes […] The post Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1783546694,
                "headline": "Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM"
              },
              {
                "id": 140846379,
                "url": "https://finnhub.io/api/news?id=00fbb6ff8e0aaeb1c8d39c660bfcfb4d4d88b6afa2f2f5290ab05a0d6347fc7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions.",
                "category": "company",
                "datetime": 1783545826,
                "headline": "Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140843476,
                "url": "https://finnhub.io/api/news?id=9f18776cd21c7c5029e062fceaa6a6e34c852ba961154849992be4fdb146027b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories (ABT) is back in focus after reporting Q1 2026 sales of US$11.16b with solid contributions from Medical Devices and issuing full year guidance that points to mid single digit comparable sales growth. See our latest analysis for Abbott Laboratories. Abbott Laboratories shares have picked up short term momentum, with a 7 day share price return of 5.62% and a 30 day share price return of 5.24%. This sits against a year to date share price decline of 22.83% and a 1 year total...",
                "category": "company",
                "datetime": 1783530581,
                "headline": "Abbott Laboratories (ABT) Q1 Sales And Guidance Put Fair Value Back In Focus"
              },
              {
                "id": 140841798,
                "url": "https://finnhub.io/api/news?id=5740a1c5e331d036b03653872fd6a74e473ae8b722d2bafbff95db75828cd58a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Abbott Laboratories (NYSE:ABT) is one of the best healthcare stocks on our list. TheFly reported on July 6 that Evercore ISI analyst Vijay Kumar reduced the firm’s price target on Abbott Laboratories to $112 from $120 while maintaining an Outperform rating on the shares. […]",
                "category": "company",
                "datetime": 1783522193,
                "headline": "Is Abbott Laboratories (ABT) Stock Still a Healthcare Growth Opportunity After Analyst Target Cut?"
              },
              {
                "id": 140852141,
                "url": "https://finnhub.io/api/news?id=29ef68bd06d5a0f3b53b18305170969b7692d1b31c33525b93970c19cefe160c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds.",
                "category": "company",
                "datetime": 1783520100,
                "headline": "5 Dividend Kings to Buy in July with Irristable Value and Yield"
              },
              {
                "id": 140835347,
                "url": "https://finnhub.io/api/news?id=7c2ba7baa099679035fad5170d750e7121c1446d52ed53d54af19195f6b4a2f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Don't sleep on these medical device leaders.",
                "category": "company",
                "datetime": 1783461000,
                "headline": "Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom"
              },
              {
                "id": 140830065,
                "url": "https://finnhub.io/api/news?id=3c61c162eeb4a4ff55bbbf7eb416d76bd56a1411992abae065eed559761e61eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Generate an immediate income that you keep regardless, plus the opportunity to buy the stock cheaper should its price fall far enough.",
                "category": "company",
                "datetime": 1783430548,
                "headline": "How To Target A 10% Yield While Catching The BSX Stock Knife?"
              },
              {
                "id": 140831550,
                "url": "https://finnhub.io/api/news?id=38d7ab3fc039fe2662f7a8274ac87455747d9c60b1ef8d0e4d601c6ce6396dbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain an attractive market for Insulet.",
                "category": "company",
                "datetime": 1783422600,
                "headline": "Insulet launches Omnipod 5 in Spain"
              },
              {
                "id": 140821137,
                "url": "https://finnhub.io/api/news?id=27663085ba23bd2d9d3fc033812df1dc7812e2db9b0e863b80eaac2e31b26fd5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1783342803,
                "headline": "Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 140819929,
                "url": "https://finnhub.io/api/news?id=dec55089042516e9c258695c07b03bef54c03da256d172e3c94c0bcbc6adbbe3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.",
                "category": "company",
                "datetime": 1783342200,
                "headline": "3 Stocks to Buy and Hold: The Long-Term Play for Your Portfolio"
              },
              {
                "id": 140821327,
                "url": "https://finnhub.io/api/news?id=70b1b8a9d036b4b523706f9e4fef269a5879a76df7fb52cb154b288d0ec06ec9",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249178311/image_2249178311.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABT",
                "summary": "Boston Scientific stock is ~60% off the highs. Read the latest analysis on the BSX stock here.",
                "category": "company",
                "datetime": 1783339189,
                "headline": "Boston Scientific: The Time Has Come To Catch This Falling Knife"
              },
              {
                "id": 140825255,
                "url": "https://finnhub.io/api/news?id=39846e6651c3bf6033381024c34fbe6c66b73d9119c1d8c9838ae5283fa863c8",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Evercore ISI Group  analyst Vijay Kumar   maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $120 to $112.",
                "category": "company",
                "datetime": 1783336170,
                "headline": "Evercore ISI Group Maintains Outperform on Abbott Laboratories, Lowers Price Target to $112"
              },
              {
                "id": 140819264,
                "url": "https://finnhub.io/api/news?id=544e132a13bd7a9e08a0f6ba63e1a9a9ab0a515999208bd55f95ce2512acc7d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "ACTON, Mass., July 06, 2026--Insulet Accelerates Global Growth with Launch of Omnipod 5 and Omnipod Discover in Spain, Expanding Access to Tubeless Diabetes Technology",
                "category": "company",
                "datetime": 1783335600,
                "headline": "Insulet Accelerates Global Growth with Launch of Omnipod® 5 and Omnipod Discover™ in Spain, Expanding Access to Tubeless Diabetes Technology"
              },
              {
                "id": 140803319,
                "url": "https://finnhub.io/api/news?id=2c90bdd8ac7913cd59660500bf0f8ea97554b2add782260b8e8aabb463800f68",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.",
                "category": "company",
                "datetime": 1783111326,
                "headline": "Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks"
              },
              {
                "id": 140802948,
                "url": "https://finnhub.io/api/news?id=b3a6f18807729852fff8b0ace8d337a6407ba5f9165cd071c70606f9c3aa2496",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181343061/image_1181343061.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABT",
                "summary": "Abbott is upgraded to Buy ahead of Q2 2026 earnings: Exact Sciences deal boosts cancer diagnostics growth as 2026 guidance improves. Click to read more.",
                "category": "company",
                "datetime": 1783094400,
                "headline": "Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering"
              },
              {
                "id": 140798933,
                "url": "https://finnhub.io/api/news?id=de9d248e34a890287b72c0a2d94ce3bd6a32f11ff52c45157e0620c835652886",
                "image": "https://www.chartmill.com/images/uploads/thumbnail_article_luc_kroeze_c1f44c837d.webp",
                "source": "ChartMill",
                "related": "ABT",
                "summary": "Quality investing strategy screening Abbott Laboratories for durable growth, high ROIC of 20.57%, strong cash flow, and sound fundamentals as a potential long-term holding.",
                "category": "company",
                "datetime": 1783080038,
                "headline": "Abbott Laboratories (NYSE:ABT) Passes the Caviar Cruise Quality Screen with Strong Growth and Profitability"
              },
              {
                "id": 140796751,
                "url": "https://finnhub.io/api/news?id=52d10b759b89283eca1f8ab7cbd1196266fc616a11af3ca1ff12ff5277923e25",
                "image": "",
                "source": "SeekingAlpha",
                "related": "ABT",
                "summary": "",
                "category": "company",
                "datetime": 1783034302,
                "headline": "Insulet Corporation: A High-Quality Growth Story Trading At A Reasonable PEG"
              },
              {
                "id": 140794039,
                "url": "https://finnhub.io/api/news?id=8831e57c447685f7d89edb07b4c239f2b6fa697dd0711d22279e85d63efc7d36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "While a guidance cut has reset expectations, several core Boston Scientific franchises are accelerating. The Neuromodulation and Interventional Oncology businesses both posted organic sales growth of 15% last quarter. This internal momentum in high-value categories contrasts sharply with the new, more cautious company-wide outlook.",
                "category": "company",
                "datetime": 1783013922,
                "headline": "What Could Push BSX Stock Higher From Here?"
              },
              {
                "id": 140792683,
                "url": "https://finnhub.io/api/news?id=3600988f2908bf843b1b2574dffe007431f29d5b0f5665c528cfeacc2fc5100f",
                "image": "",
                "source": "Fintel",
                "related": "ABT",
                "summary": "",
                "category": "company",
                "datetime": 1783012114,
                "headline": "Baird Initiates Coverage of Abbott Laboratories (ABT) with Outperform Recommendation"
              },
              {
                "id": 140790534,
                "url": "https://finnhub.io/api/news?id=5c03e2ad6b3a40cd83b038e99675a36e8b4c6fe632f1f35d49964e68112a9714",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Passive income is characterized by its ability to generate revenue without requiring the earner’s continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence. The more passive income can help cover rising costs, such as mortgages, insurance, taxes, and other expenses, the easier it ... 5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return Potential",
                "category": "company",
                "datetime": 1782994719,
                "headline": "5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return Potential"
              },
              {
                "id": 140785913,
                "url": "https://finnhub.io/api/news?id=652c224fb72005ebbe214e8e25bf5a9f5965cd2454db147b19e8c36064060f8c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Grail is awaiting an FDA ruling on a cancer screening test, but already more tests are finding their way into medical practices.",
                "category": "company",
                "datetime": 1782943320,
                "headline": "When Multi-Cancer Blood Screens Could Finally Take Off"
              },
              {
                "id": 140784766,
                "url": "https://finnhub.io/api/news?id=743afbc3e837d1d7b75c4e2e717a37546078284f1ff22ad70e2cc0ff42d0387e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott's broad healthcare reach and Intuitive's robotic surgery focus present distinct financial strengths and risks for investors weighing portfolio strategy.",
                "category": "company",
                "datetime": 1782937735,
                "headline": "Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140783746,
                "url": "https://finnhub.io/api/news?id=9680f6fbf3e6f19db5f9c281b6f0a7c2715697ca3e49b86f57756cbab870ee43",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "The U.S. Department of Justice has closed its criminal investigation into Abbott Laboratories' Michigan baby formula plant. Authorities are pursuing civil penalties tied to alleged manufacturing failures that contributed to a national baby formula shortage. The outcome clarifies a key regulatory risk and shifts the focus to civil, rather than criminal, enforcement. Abbott Laboratories, ticker NYSE:ABT, now faces a clearer regulatory path as the criminal probe gives way to civil penalties...",
                "category": "company",
                "datetime": 1782933012,
                "headline": "Abbott (ABT) Clears A Major Legal Risk As DOJ Ends Criminal Formula Probe"
              },
              {
                "id": 140782663,
                "url": "https://finnhub.io/api/news?id=ff45f411c29c615adb3dc0a8d2c62b15c4cf30676246ebf27dbcdf71a02a6f47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Investing.com -- Baird initiated coverage of Abbott Laboratories with an \"Outperform\" rating and a $121 price target, saying the diversified healthcare company's portfolio and upcoming product launches position it for stronger earnings growth despite near-term headwinds.",
                "category": "company",
                "datetime": 1782927202,
                "headline": "Baird starts Abbott at Outperform, sees product pipeline driving growth"
              },
              {
                "id": 140795677,
                "url": "https://finnhub.io/api/news?id=d985554a366bdec2f620ec8c7904a90d0d9b3b59543b86c00cf22bcea0939419",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "https://www.fda.gov/vaccines-blood-biologics/substantially-equivalent-510k-device-information/bk261345-hiv-combo-next-assay",
                "category": "company",
                "datetime": 1782912488,
                "headline": "FDA Approves Abbott HIV Combo Next Assay Under 510(k) BK261345 On June 29, 2026"
              },
              {
                "id": 140779524,
                "url": "https://finnhub.io/api/news?id=5da200476290b6a2792ab4e8c317b4b00717f68aee6a0e6c50890500618d9cbd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "SAN DIEGO, July 01, 2026--The t:slim X2™ insulin pump from Tandem Diabetes Care is now compatible with Abbott’s FreeStyle Libre 3 Plus CGM sensor in five EU countries.",
                "category": "company",
                "datetime": 1782909000,
                "headline": "Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets"
              },
              {
                "id": 140778972,
                "url": "https://finnhub.io/api/news?id=3380f2a1d9b1e63f470e0b498e123dc16c769b6a39ce7b540f4e76699f7ca830",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Pre-Market Stock Futures: Futures are trading lower as we get ready to start the third quarter after a record-setting second quarter that saw the Dow Jones Industrial Average close at 52,317, up 0.26% to finish the venerable index’s best first half since 2021, while the Nasdaq finished the session at 26,213, up 1.52% for the ... Here Are Wednesday’s Best Wall Street Analyst Research Calls: Abbott Laboratories, Circle Internet, Dow, Kratos Defense, Lockheed Martin, Salesforce, ServiceNow,SpaceX,",
                "category": "company",
                "datetime": 1782907394,
                "headline": "Here Are Wednesday’s Best Wall Street Analyst Research Calls: Abbott Laboratories, Circle Internet, Dow, Kratos Defense, Lockheed Martin, Salesforce, ServiceNow,SpaceX, and More"
              },
              {
                "id": 140780304,
                "url": "https://finnhub.io/api/news?id=2b6f958a15d0e51ee111fe09042652dfb2441f49384e3c3584aa8460aa6bd4b9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/01/Abbott-Laboratories.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Top Wall Street analysts changed their outlook on top names. See the latest analyst ratings and coverage on stocks like ABT, LIVN, AMPL, LION, and HONA.",
                "category": "company",
                "datetime": 1782889334,
                "headline": "This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday"
              },
              {
                "id": 140781392,
                "url": "https://finnhub.io/api/news?id=2e9e1e3921a229126a64d277876c7dd37ea93fa4c073f169bc7f5d2facfdd6f0",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "Baird  analyst David Rescott   initiates coverage on Abbott Laboratories (NYSE:ABT) with a Outperform rating and announces Price Target of $121.",
                "category": "company",
                "datetime": 1782880520,
                "headline": "Baird Initiates Coverage On Abbott Laboratories with Outperform Rating, Announces Price Target of $121"
              },
              {
                "id": 140772045,
                "url": "https://finnhub.io/api/news?id=1f5603b025191ca654430a803bb9ef76e69d5f23f2eb2c753a7d1464b19a03eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories has reached a proposed settlement that will see civil penalties paid under the US False Claims Act.",
                "category": "company",
                "datetime": 1782827821,
                "headline": "US criminal probe into Abbott infant-formula plant closed"
              },
              {
                "id": 140767860,
                "url": "https://finnhub.io/api/news?id=219417d76a75c6f70ad40fe874498b12913da44cbcc6047ea07efc6ecdeb0ece",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "The latest trading day saw Abbott (ABT) settling at $92.71, representing a -1.5% change from its previous close.",
                "category": "company",
                "datetime": 1782769803,
                "headline": "Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know"
              },
              {
                "id": 140766835,
                "url": "https://finnhub.io/api/news?id=cfa77da23f74bea80935a0030d726ae336db01f7885ff7a61d0aed12e4996a6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index up 0.1% and the",
                "category": "company",
                "datetime": 1782763147,
                "headline": "Sector Update: Healthcare Stocks Higher Late Afternoon"
              },
              {
                "id": 140764106,
                "url": "https://finnhub.io/api/news?id=f4fbe12de44dd4368caac0162ec6b1a256f57d5dae0fc7960291663304ece869",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Hematologic Malignancies Testing Market size & share revenue was valued at approximately USD 3.28 Billion in 2025 and is expected to reach USD 3.72 Billion in 2026 and is expected to reach around USD 12.47 Billion by 2035, at a CAGR of 14.4% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Abbott Laborato",
                "category": "company",
                "datetime": 1782754200,
                "headline": "Global Hematologic Malignancies Testing Market Size/Share Worth USD 12.47 Billion by 2035 at a 14.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)"
              },
              {
                "id": 140764119,
                "url": "https://finnhub.io/api/news?id=2558ab0870b5c4bd52b22a6d7cbb6ec5c9eb3d3645adb5a45d03774f7d39dc10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Edwards Lifesciences (EW) can sustain a high revenue growth rate given its technological leadership",
                "category": "company",
                "datetime": 1782750579,
                "headline": "Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says"
              },
              {
                "id": 140762660,
                "url": "https://finnhub.io/api/news?id=becaee42812cb4ad28486e3b8968e7258bbc74f949bb8d11bade672d221da7ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "(Updates with DOJ's response in the fifth and sixth paragraphs.) Abbott Laboratories (ABT) will n",
                "category": "company",
                "datetime": 1782743505,
                "headline": "Update: Market Chatter: Abbott Laboratories Baby Formula Probe Dropped by DOJ After Years-Long Investigation Into Contamination Risks"
              },
              {
                "id": 140762661,
                "url": "https://finnhub.io/api/news?id=436a621c27ef4c5a4c8af1390e6ab512fb77305db81ffffa5d81207c83cb97fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "ABT's Medical Devices unit builds on strong growth with new diabetes, heart rhythm and electrophysiology advances ahead of Q2 2026.",
                "category": "company",
                "datetime": 1782739200,
                "headline": "How Abbott's Largest Segment Is Preparing for the Next Growth Phase"
              },
              {
                "id": 140764120,
                "url": "https://finnhub.io/api/news?id=15115c8ddf386bc50ddc3fb9d01795b6c1cbd80a889b327a585df6d4ea69da48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.",
                "category": "company",
                "datetime": 1782731798,
                "headline": "Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic"
              },
              {
                "id": 140760878,
                "url": "https://finnhub.io/api/news?id=a94ba20b084baed9a6af46518a49edb8a545df34a6d547b6e213059448651a8e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories (ABT) will not face criminal charges after the US Department of Justice closed a",
                "category": "company",
                "datetime": 1782726681,
                "headline": "Market Chatter: Abbott Laboratories Baby Formula Probe Dropped by DOJ After Years-Long Investigation Into Contamination Risks"
              },
              {
                "id": 140762849,
                "url": "https://finnhub.io/api/news?id=467a445cb14d55ec14fff1316fd9ca105b05663fa3c00f41b4090cd25d95131b",
                "image": "",
                "source": "Benzinga",
                "related": "ABT",
                "summary": "https://www.wsj.com/us-news/law/the-baby-formula-probe-produced-a-pile-of-evidence-then-the-doj-dropped-the-case-cdc68716 ",
                "category": "company",
                "datetime": 1782701695,
                "headline": "'The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case' - WSJ"
              },
              {
                "id": 140746315,
                "url": "https://finnhub.io/api/news?id=d4d528b7fb22e3ba19c52c0d05c463a1321f68dc3f85b8f2808007bb389b0dfa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "Abbott Laboratories (NYSE:ABT) is among the Best Brain-Computer Interface Stocks. On June 4, Reuters reported a federal judge ‌ruled that Abbott Laboratories (NYSE:ABT) must face a proposed class-action lawsuit alleging it misled consumers by marketing PediaSure Grow & Gain drinks as “clinically proven” to help children grow. US District Judge Paul Engelmayer said labeling featuring a […]",
                "category": "company",
                "datetime": 1782574334,
                "headline": "Abbott Laboratories (ABT) must face a Lawsuit over PediaSure, Statements about Children’s Growth"
              },
              {
                "id": 140744456,
                "url": "https://finnhub.io/api/news?id=403df238f4180d4ffcc793e042128445deb30b376be9de6e40c4d1f208d13d3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABT",
                "summary": "How Abbott Laboratories Stock Has Been Performing Abbott Laboratories has attracted fresh attention from investors after a recent rebound in its share price, raising the question of whether the current level reflects fair value or an opportunity. Over the past week the stock gained 6.5%, with a 9.9% rise over the last 30 days, although returns since the start of the year are down 24.2% and the one year return is down 28.5%. This gives important context to the recent strength. These moves have...",
                "category": "company",
                "datetime": 1782544117,
                "headline": "Abbott Laboratories (ABT) Stock After Recent Rebound Is There Still Value Left"
              },
              {
                "id": 140744963,
                "url": "https://finnhub.io/api/news?id=d502d3e234636610a86a46fb082cae7d5af2639e1594755baf12d54b8bc8d7f9",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABT",
                "summary": "Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.",
                "category": "company",
                "datetime": 1782541720,
                "headline": "Best Dividend Aristocrats: June 2026"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 6,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.8,
            "source_article_count": 166,
            "discarded_article_count": 138
          },
          "sentimentPoints": 8
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 22.5,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.4,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.4,
            "vcp_reason": "站上MA50；升放量(近10日4日)；收盤突破20日高位；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 7,
              "vol_ref": 14111446.666666666,
              "down_days": 2,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 14994580,
              "avg_vol_20": 13110925,
              "avg_vol_30": 14111446.666666666,
              "range_pct_10": 0.15815643526486906,
              "range_pct_20": 0.15815643526486906,
              "range_pct_30": 0.16360680818512158,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 4,
              "breakout_20d_ok": true,
              "vol_ratio_10_30": 1.0625827637799479,
              "dist_to_20d_high": -0.0038395085429064257,
              "down_shrink_days": 2,
              "breakout_level_20d": 104.18,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.9666861484511976
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 3.2,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.943392618091413,
              "turnoverUsdM": 1611.9377643599998,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.8,
          "stopLevels": {
            "symbol": "US.ABT",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 98.4236,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.7,
            "stop_loss_percent": 5.9,
            "take_profit_price": 115.1895,
            "target_multiplier": 2.2,
            "technical_strength": 2.35,
            "take_profit_percent": 10.1
          },
          "positionPoints": 1.8,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.7157072314989281,
          "stopLossPercent": 5.886785236182826,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.ABT",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 3.0782,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.94
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 140.71
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.1101
    },
    "kdj": {
      "d": 80.54,
      "j": 103.29,
      "k": 88.12,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 61.2
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 11605842,
      "recentSlope": 11781614.2,
      "previousSlope": -952550
    },
    "rsi": 66.5,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 92.5651,
      "position": "SAR喺價下",
      "distancePct": 11.49,
      "previousTrend": "上升"
    },
    "ma50": 91.6962,
    "macd": {
      "macd": 3.162928119847706,
      "trend": "強烈看漲",
      "signal": 2.3389841544063947,
      "histogram": 0.8239439654413112
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 96.7114,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 8
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.18,
      "score": 6,
      "avgVolume": 13058342,
      "currentVolume": 15413442
    },
    "derived": {
      "ma20": 96.3075,
      "ma50": 91.6962,
      "prevClose": 103.06,
      "avgVolume10": 15360304,
      "avgVolume20": 13058342,
      "changePercent": 1.47,
      "avgVolumeForScore": 13058342
    },
    "ma_cross": {
      "ma20": 96.3075,
      "ma50": 91.6962,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 95.7845,
      "prevMa50": 91.2812,
      "spreadPct": 5.03,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 87.2351,
      "upper": 105.3799,
      "position": "上半部"
    },
    "rsi_short": 74.75,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.18
    }
  }
}

{
  "close": 104.58,
  "volume": 15413442,
  "changePercent": 1.47
}